---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-102607"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:08:49.578448+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neuphoria adopts poison pill after investor accumulates >20%; launches strategic review

## Summary
- Rights plan triggered if any entity acquires 15%+ beneficial ownership without board approval.
- Adopted after an individual investor disclosed >20% ownership as of Oct 23, 2025.
- Rights expire Oct 27, 2026; no dead-hand/slow-hand provisions.
- Board also evaluating strategic alternatives to maximize stockholder value.

## SEC filing metadata
- accession: 0001213900-25-102607
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/0001213900-25-102607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/ea0262561-8k_neuphoria.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-102607
- JSON: https://secwatch.observer/filing/0001213900-25-102607.json
- Plain text: https://secwatch.observer/filing/0001213900-25-102607.txt

## Key facts
- Equity Issuances
  Neuphoria Therapeutics Inc. issued common stock.
  - Security: common stock
  source text: the Board declared a dividend of one preferred share purchase right for each outstanding share of the Company’s common stock as of the close of business on October 27, 2025, the record date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/0001213900-25-102607-index.htm
- Governance Changes
  Neuphoria Therapeutics Inc.: Adoption of Certificate of Designations establishing Preferred Shares and their rights (effective 2025-10-27).
  - Change: charter amendment
  - Effective: 2025-10-27
  source text: Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the adoption of the Rights Agreement referenced in Item 1.01 above, the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October 27, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/0001213900-25-102607-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.